Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development Brains Bioceutical expands its cannabinoid API portfolio with new D9-THC, CBN, and CBG offerings, driving innovation in drug development and research

Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to its Animal Health Division VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Today marks a pivotal development for Brains Bioceutical Corp ("Brains Bio"), as it significantly strengthens its Veterinary Health...

Prati-Donaduzzi Secures the Largest Global Pharma Supply Agreement for Natural Cannabinoids with API Manufacturer Brains Bioceutical VANCOUVER, British Columbia, April 04, 2023 (GLOBE NEWSWIRE) -- Brains Bioceutical Corp (“Brains Bio” or the “Company”), the largest natural cannabinoid active pharmaceutical ingredient (“API”)...